Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Rethinks Ganitumab After Longshot Pancreatic Cancer Trial Fails

Executive Summary

Hopes for IGF-1R inhibitor ganitumab had not been high due to past flops for others in the class. But research in extensive stage small-cell lung cancer and KRAS wild-type metastatic colorectal cancer goes on, at least for now.

You may also be interested in...

Deal Watch: Roche/Foundation Medicine Highlights Hyper Deal-Making During J.P. Morgan

Biogen will purchase GSK spinout Convergence to bolster its pain portfolio, while Tekmira and OnCore are merging to create a new company focused on hepatitis B. Two J&J units struck deals during the week in Alzheimer’s and gastrointestinal indications, as Lilly teamed up with Merck and Bristol for combo trials to keep its drugs relevant in the PD-1 world.

Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace

Amgen explains why it has what it takes in immunotherapy, as part of a broader oncology development plan.

Celgene’s Abraxane Scores A Win Against Tough Pancreatic Cancer

Abraxane more than doubled two-year survival and conferred a near-two-month overall survival advantage against pancreatic cancer compared with standard of care gemcitabine alone in the Phase III MPACT trial, presented Jan. 25 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Celgene plans global regulatory filings by mid-2013.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts